然而,考虑到HER2-low和HER2 0乳腺癌的HR阳性患者比HR阴性患者更晚出现该峰值,整个队列复发峰值的差异可能是由于HER2-low乳腺癌病例中HR阳性患者的比例更高,以及内分泌治疗对这些患者的影响。 考虑到HER2-low和HR阳性之间的正相关 (O...
然而,考虑到HER2-low和HER2 0乳腺癌的HR阳性患者比HR阴性患者更晚出现该峰值,整个队列复发峰值的差异可能是由于HER2-low乳腺癌病例中HR阳性患者的比例更高,以及内分泌治疗对这些患者的影响。 考虑到HER2-low和HR阳性之间的正相关 (OR=3.1),以及校正HR状态后pCR率和DFS 无差异(多变量分析中P=0.07),HER2-low乳腺...
[1] Prat A, Bardia A, Curigliano G, et al. An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without HER2 Amplification (HER2-Low). JAMA Oncol. Published online September 15, 2022....
[3]Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [4]Tarantino P, Jin Q, Tayob N,...
A score of 0 or 1+ indicates no or low expression of Her2, while a score of 2+ is considered equivocal and requiresfurther testing. A score of 3+ indicates high expression of Her2. FISH is a molecular technique that examines the genetic material of tumor cells to determine the presence ...
HER2-Low status was defined as immunohistochemistry score 1 + or 2+ without in situ hybridization amplification. Pooled hazard ratios (HRs) for survival endpoints in the metastatic [progression-free survival (PFS), overall survival (OS)] and in the early [disease free-survival (DFS) and OS]...
?LuminalA:ER+and/orPR+,HER2-,andlowKi67＜(14%)；?LuminalB:ER+and/orPR+,HER2；+ER+and/orPR+,HER2-andhighKi6（7≥14%）；?HER2(+):ER-,PR-,HER2+；?Basal-like:ER-,PR-,HER2-,andCK5/6and/or EGFR；+?Normalbreast-like:ER-,PR-,HER2,CK5/6,EGFR,CK14,CK均1-7。国际共识HER2检测...
[1]Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. [2]Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in Her2 immunohistochemistry-negative bre...
[8] Spring LM, Barlow WE, Bardia A, et al. Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Anton...
the prevalence of HER2-low (ie, HER2 1+ and HER2 2+ without amplification) and its correlation with clinical and histopathological features, other biomarkers' status, including mismatch repair/microsatellite instability status, Epstein-Barr encoding region (EBER) and PD-L1 Combined Positive Score. Re...